The importance of using core outcome measures during therapeutic studies of eosinophilic esophagitis - 03/02/22
Doi : 10.1016/j.jaci.2021.09.025
David A. Hill, MD, PhD ⁎ 
Division of Allergy and Immunology, Children’s Hospital of Philadelphia, and the Department of Pediatrics and Institute for Immunology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pa
∗Corresponding author: David A. Hill, MD, PhD, Division of Allergy and Immunology, Children’s Hospital of Philadelphia, Abramson Research Building, 1208B, 3615 Civic Center Blvd, Philadelphia, PA 19104.Division of Allergy and ImmunologyChildren’s Hospital of PhiladelphiaAbramson Research Building1208B3615 Civic Center BlvdPhiladelphiaPA19104
Key words : Eosinophilic esophagitis, clinical trial, core outcomes set
Le texte complet de cet article est disponible en PDF.
| Research in the Hill Lab is funded by the National Institutes of Health (grants DK116668, DK129418, and AI045008), Children’s Hospital of Philadelphia Research Institute, American Academy of Allergy, Asthma & Immunology, American Partnership for Eosinophilic Disorders, and the Food Allergy Fund. The views expressed in this editorial are those of the author and do not represent the official views of the National Institutes of Health or other funders. |
|
| Disclosure of potential conflict of interest: The author declares that he has no relevant conflicts of interest. |
© 2021
American Academy of Allergy, Asthma & Immunology. Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 149 - N° 2
P. 541-542 - février 2022 Retour au numéro
Article précédent
- Immune checkpoint skewing might be the cause of continuous immune activation in nasal polyps: New opportunities for therapies
- Alex KleinJan
- The new quest in CTLA-4 insufficiency: How to immune modulate effectively?
- Emma Westermann-Clark, Mark Ballow, Jolan E. Walter
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?